Diacerein for epidermolysis bullosa simplex

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 10 Oct 2023: Trial registered, NCT06073132
  2. 4 Apr 2024: Trial started, NCT06073132

The trials

NCT06073132: An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

State
Under way
Phase
Phase 2 and Phase 3
People
80 planned
Started
4 Apr 2024
Primary completion
10 Jun 2026
Arms
Part A AC-203, Part B AC-203
Results
None posted
  1. 10 Oct 2023: Trial registered
  2. 4 Apr 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Artrodar, Diora, Fisiodar, Verboril, Zondar.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.